Condensed Consolidated Statements Of Redeemable Noncontrolling Interests and Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Total	Convertible Promissory Notes [Member]	Columbia stock purchase agreement [Member]	Series C And Series D Financing [Member]	IPO [Member]	Hurdle Share Option Plan [Member]	Redeemable Noncontrolling Interests [Member]	Redeemable Noncontrolling Interests [Member] Convertible Promissory Notes [Member]	Redeemable Noncontrolling Interests [Member] Columbia stock purchase agreement [Member]	Redeemable Noncontrolling Interests [Member] Series C And Series D Financing [Member]	Redeemable Noncontrolling Interests [Member] IPO [Member]	Redeemable Noncontrolling Interests [Member] Hurdle Share Option Plan [Member]	Common Stock [Member]	Common Stock [Member] Convertible Promissory Notes [Member]	Common Stock [Member] Columbia stock purchase agreement [Member]	Common Stock [Member] Series C And Series D Financing [Member]	Common Stock [Member] IPO [Member]	Common Stock [Member] Hurdle Share Option Plan [Member]	Additional Paid-In Capital [Member]	Additional Paid-In Capital [Member] Convertible Promissory Notes [Member]	Additional Paid-In Capital [Member] Columbia stock purchase agreement [Member]	Additional Paid-In Capital [Member] Series C And Series D Financing [Member]	Additional Paid-In Capital [Member] IPO [Member]	Additional Paid-In Capital [Member] Hurdle Share Option Plan [Member]	Share Subscriptions Receivable [Member]	Share Subscriptions Receivable [Member] Convertible Promissory Notes [Member]	Share Subscriptions Receivable [Member] Columbia stock purchase agreement [Member]	Share Subscriptions Receivable [Member] Series C And Series D Financing [Member]	Share Subscriptions Receivable [Member] IPO [Member]	Share Subscriptions Receivable [Member] Hurdle Share Option Plan [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Accumulated Other Comprehensive Income (Loss) [Member] Convertible Promissory Notes [Member]	Accumulated Other Comprehensive Income (Loss) [Member] Columbia stock purchase agreement [Member]	Accumulated Other Comprehensive Income (Loss) [Member] Series C And Series D Financing [Member]	Accumulated Other Comprehensive Income (Loss) [Member] IPO [Member]	Accumulated Other Comprehensive Income (Loss) [Member] Hurdle Share Option Plan [Member]	Accumulated Deficit [Member]	Accumulated Deficit [Member] Convertible Promissory Notes [Member]	Accumulated Deficit [Member] Columbia stock purchase agreement [Member]	Accumulated Deficit [Member] Series C And Series D Financing [Member]	Accumulated Deficit [Member] IPO [Member]	Accumulated Deficit [Member] Hurdle Share Option Plan [Member]	Total Stockholders' Equity Attributable to ATAI Life Sciences N.V. Stockholders [Member]	Total Stockholders' Equity Attributable to ATAI Life Sciences N.V. Stockholders [Member] Convertible Promissory Notes [Member]	Total Stockholders' Equity Attributable to ATAI Life Sciences N.V. Stockholders [Member] Columbia stock purchase agreement [Member]	Total Stockholders' Equity Attributable to ATAI Life Sciences N.V. Stockholders [Member] Series C And Series D Financing [Member]	Total Stockholders' Equity Attributable to ATAI Life Sciences N.V. Stockholders [Member] IPO [Member]	Total Stockholders' Equity Attributable to ATAI Life Sciences N.V. Stockholders [Member] Hurdle Share Option Plan [Member]	Noncontrolling Interests [Member]	Noncontrolling Interests [Member] Convertible Promissory Notes [Member]	Noncontrolling Interests [Member] Columbia stock purchase agreement [Member]	Noncontrolling Interests [Member] Series C And Series D Financing [Member]	Noncontrolling Interests [Member] IPO [Member]	Noncontrolling Interests [Member] Hurdle Share Option Plan [Member]
Beginning Balance at Dec. 31, 2019							$ 142
Beginning Balance at Dec. 31, 2019	$ 59,638												$ 10,510						$ 69,819						$ 0						$ (1,426)						$ (20,152)						$ 58,751						$ 887
Beginning Balance, Shares at Dec. 31, 2019													90,709,312
Settlement of issuance of common shares value							0
Issuance of common shares, net of issuance costs	77,212												$ 1,756						75,456						0						0						0						77,212						0
Issuance of common shares, net of issuance costs ,Shares													14,933,344
Exercised													320,000
Exercise of stock options	120						0						$ 38						82						0						0						0						120						0
Issuance of noncontrolling interest	12,312		$ 120				0						0						0		$ 120				0						0						0						0		$ 120				12,312
Issuance of common shares in connection with the conversion of 2020 Convertible Promissory Notes (Note 11), shares														8,773,056
Issuance of common shares in connection with the conversion of 2020 Convertible Promissory Notes (Note 11), Value		$ 50,059						$ 0						$ 1,068						$ 48,991						$ 0						$ 0						$ 0						$ 50,059						$ 0
Issuance of subsidiary shares in connection with the Columbia stock purchase agreement (Note17)	(12,312)		$ (120)				0						0						0		$ (120)				0						0						0						0		$ (120)				(12,312)
Stock-based compensation expense	67,158						0						0						67,158						0						0						0						67,158						0
Foreign currency translation adjustment, net of tax	7,232						0						0						0						0						7,245						0						7,245						(13)
Net income (loss)							(142)
Net income (loss)	$ (178,483)												$ 0						0						0						0						(169,843)						(169,843)						(8,640)
Ending Balance, Shares at Dec. 31, 2020	7,052,003												114,735,712
Ending Balance at Dec. 31, 2020	$ 95,368												$ 13,372						261,626						0						5,819						(189,995)						90,822						4,546
Ending Balance at Dec. 31, 2020	0						0
Issuance of common shares, net of issuance costs	140,868			$ 23,510	$ 231,581	$ 0	0			$ 0	$ 0	$ 0	$ 0			$ 1,881	$ 2,046	$ 0	0			$ 162,497	$ 229,535	$ 0	140,868			$ (140,868)			0			$ 0	$ 0	$ 0	0			$ 0	$ 0	$ 0	140,868			$ 23,510	$ 231,581	$ 0	0			$ 0	$ 0	$ 0
Issuance of common shares, net of issuance costs ,Shares													0			15,552,688	17,250,000	7,281,376
Exercised													379,049
Exercise of stock options	935					$ 534	0						$ 45					$ 12	890					$ 522	0					$ 0	0					$ 0	0					$ 0	935					$ 534	0					$ 0
Issuance of noncontrolling interest	8,411						2,555						0						0						0						0						0						0						8,411
Issuance of subsidiary shares in connection with the Columbia stock purchase agreement (Note17)	(8,411)						(2,555)						0						0						0						0						0						0						(8,411)
Conversion of convertible notes to common stock	7,259												$ 646						6,613																								7,259
Conversion of convertible notes to common stock, Shares													5,478,176
Stock-based compensation expense	63,362						0						$ 0						63,362						0						0						0						63,362						0
Foreign currency translation adjustment, net of tax	(14,179)						0						0						0						0						(14,155)						0						(14,155)						(24)
Net income (loss)							(2,555)
Net income (loss)	(171,690)												$ 0						0						0						0						(167,808)						(167,808)						(3,882)
Ending Balance, Shares at Dec. 31, 2021													160,677,001
Ending Balance at Dec. 31, 2021	385,959												$ 18,002						$ 725,045						$ 0						$ (8,336)						$ (357,803)						$ 376,908						$ 9,051
Ending Balance at Dec. 31, 2021	$ 0						$ 0